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To evaluate the role of vitamin A on B lymphocytes, natural killer cells and 
haematological parameters including the activation marker(l2) in HIV-1 
seropositive pregnant women. 
Patients and Methods: 
Baseline, delivery or 6 weeks post supplementation, 1 week post- partum and 3 
month post-partum samples were collected from subjects. Patients were treated 
with vitamin A and beta-carotene or placebo after the baseline bloods were 
collected and were supplemented with a bolus dose one day post delivery. For 
the purposes of this study the delivery and 6 weeks post supplementation 
samples were grouped as delivery samples. Quantification of B lymphocytes, 
the activation marker (12) and natural killer cells were measured by flow 
cytometry, using CD19, I2(HLA-DR) and CD56 monoclonal antibodies 
respectively in a random subsample of 208 patients drawn from a cohort of 400 
HIV-1 positive subjects. 
Vitamin A levels at baseline and complete blood cell counts were also evaluated. 
In this cohort a vitamin A level of <40ug/dl was considered low normal and 
<20ug/dl was considered deficient. 
Results: 
B lymphocyte counts were lower during pregnancy and recovered between 1 
week and 3 months post delivery. While natural killer cell counts were 
comparable at baseline, the placebo group did not change significantly at any of 
the intervals studied, but the vitamin A group showed a rise at 1 week post 
delivery and a subsequent fall. The activation marker (12) did not show any 
significant change in both groups. In the vitamin A group 37. 5% ( 15 out 40) and 
in the placebo group 38.5% (20 out of 52) had retinol levels of <20ug/dl. Fifty 
percent of the patients in the vitamin A group and 55. 7% in the placebo group 
had low normal retinol levels. The mean retinol levels prior to intervention were 
25.65 ug/dl (95% Cl =21. 71 ➔29.60) in the vitamin A group and 24.38 ug/dl 
(Cl=21.80➔26.97) in the placebo group; both groups were comparable at 3 
months post partum. At baseline 65.4% (136 out of 208) patients were anaemic; 
this corrected at 3 months post partum. Six patients had thrombocytopenia at 
baseline. At 3 months the two groups were comparable with platelet counts 
within expected normals in the post partum period. Leucopenia was noted in 
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5.2% (11 out of 208) patients at baseline with counts <5.0 X 109/1. At 3 months 
the two groups were comparable with a mean white cell count of 5.62 X 109/1 in 
the vitamin A group and 5.56 X 109/1 in the placebo group which was 
significantly lower than the baseline levels(vitamin A -7.80 X109/1 and placebo-
7.92 X 109/1). Lymphopenia was noted in 9.1 % (19 out of 208) patients at 
baseline. A significant increase was noted at 3 months post partum in the two 
groups. 
Conclusion: 
There was no significant effect of vitamin A on 8 lymphocytes. Natural killer cells 
in the vitamin A group increased more than in the placebo group but this 
"booster'' effect by vitamin A was very transient. No difference was noted in the 
activation marker between the 2 groups at any point. The cellular changes with 
pregnancy, in HIV+ patients in this study are the same as in HIV- patients. No 
beneficial or detrimental effect was noted on natural killer cells, B lymphocytes 




1.1 Vitamin A: 
During the 1920s and 1930s, vitamin A became known as the "anti-infective" 
vitamin, and the first attempts were made then to use it therapeutically during 
infectious illnesses. Vitamin A deficiency is the leading cause of xerophthalmia, 
visual impairment and nutritional blindness in children (1,2), and has emerged 
as a major cause of childhood mortality and morbidity in the developing 
world(3). Pregnancy and HIV infection are risk factors for vitamin A 
deficiency(4). As a single intervention vitiamin A therapy may alter disease 
morbidity even when other concurrent macro- and micronutrient deficiencies are 
not corrected(S). It may also have significant immune effects in hosts who are 
not deficient in this micronutrient. Vitamin A when administered, may also have 
protective effects in various other disease states such as bronchopulmonary 
dysplasia, alcoholism and cancer. Vitamin A is an important modulator of the 
immune system being responsible for growth, cellular differentiation, 
maintenance of epithelial surfaces, reproduction and vision(6, 7), as well as 
cytokine production.(8). Vitamin A deficiency and hypovitaminosis have been 
shown to impair immune responses(8). Vitamin A is bound to its physiological 
carriers, retinol binding protein (RBP), cytoplasmic retinol binding protein 
(CRBP), retinoic acid receptor (RAR) and retinoic X receptor (RXR) which is 
essential for the growth of activated human B cells(9). 
Hypovitaminosis is associated with compromised 8-cell haematopoiesis and 
impaired humeral immunity. Vitamin A deficiency and hypovitaminosis have 
been shown to impair normal immune cytokine production which enhance B-cell 
activation. HIV infection is associated with multiple nutritional deficiencies, 
including Vitamin A(10). Vitamin A deficiency has also been implicated as a risk 
factor for increased mortality during infancy and in the perinatal period(11 ), and 
as a risk factor for mother to infant transmission of HIV in developing 
countries(12). Vitamin A influences the numbers and nature of white cells 
involved in immune, inflammatory and wound healing processes(13). 
Liver, cod liver oil, and dairy products are good sources of preformed vitamin A 
alcohol (retinol). Green leafy vegetables, carrots, and fruits such as mangoes 
are sources of carotenoids such as P-carotene, which are converted to retinal in 
the intestine. Many plant carotenoids, such as f3-carotene and p-cryptoxanthin 
can be converted to vitamin A by an oxygenase present in the intestine and 
elsewhere. Carotenoids are detectable in various tissues, but unlike vitamin A 
they do not combine with specific transport proteins and are transported mainly 
as non-polar lipids(14). 
Retinol receptors are present on cells of many different body tissues. In 
intracytoplasmic spaces retinol is converted to its active metabolites, retinoic acid 
and retinal. These metabolites in turn bind to specific intranuclear receptors that 
modulate cellular activities. Decreased serum vitamin A content is noted in a 
wide variety of infective and febrile conditions. This is probably a manifestation 
of the acute phase response. Large oral doses of vitamin A have reduced 
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measles morbidity and mortality(15). Vitamin A supplementation has improved 
immune function as shown by speedier reversal of measles induced 
lymphopenia and by improvement of the measles lgG antibody response during 
the acute phase of the disorder(16). Retinoic acid is probably the physiologically 
important metabolite for sustaining lgG immune responses in vivo(17). Reduced 
liver stores of vitamin A are noted following infections and the low levels may be 
due to anorexia, decreased absorption, increased metabolic requirements, or 
increased catabolism. Plasma and liver levels of vitamin A are often used for 
investigational purposes and in the absence of clinical manifestations plasma 
levels below 0.7 umol/1 (20 ug/dl) reflect vitamin A deficiency. Levels below 1,05 
umol/1 (30 ug/dl) may be associated with compromised biological action of retinol. 
A single high oral dose of the vitamin may replenish liver stores. Excessive 
vitamin A administration to pregnant women during the first trimester may be 
teratogenic(S), and extremely high intake may lead to signs of chronic toxicity. 
This is manifested by bone pain, dry skin and anorexia. Beta-carotene 
supplementation improves some indices of immune response, including 
increasing numbers of circulating Natural Killer cells in humans with inadequate 
vitamin A intake or with a previously stressed immune response(18). Low 
vitamin A levels have also been reported in many other infectious conditions, eg. 
tuberculosis, schistosomiasis, malaria, leprosy, rheumatic fever, otitis media, 
gastrointestinal and respiratory infections(S). Vitamin A is vital for maintenance 
of mucosa! integrity and immunity. In both humans and animals who are vitamin 
A deficient lymphocytes have collectively expressed fewer activation markers 
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and at times displayed reduced mitogen-induced proliferation(19). Abnormal 
specific lgG subclass proportions have also been described in vitamin A 
deficiency, and this may also relate to reduced clonal expansion of specific B cell 
subsets in response to alterations in T cell cytokine production. Abnormal 
peripheral blood lymphocyte proportions in vitamin A deficient rats were 
corrected by retinoic acid supplementation (19). Rats with induced vitamin A 
deficiency showed decrease in the proliferative response of B cells but no 
decrease in T cell response was observed. 
Beta-carotene is a non-toxic compound whose main side-effect, when taken in 
high doses, is a benign and reversible yellowing of the skin (hypercarotenaemia). 
Mechanisms of action of beta-carotene include quenching of oxygen free 
radicals, improved cell to cell communication, modulation of lipo-oxygenase 
activity, increased cytokine release and stabilization of lysosomal 
membranes(20). Beta-carotene may play a more important role than retinal in 
HIV-1 infected patients(21 ). Vitamin A together with beta-carotene in HIV­
positive women could greatly reduce viraemia(22); and an increased viral load 
has been previously shown to increase the risk of vertical transmission(23). 
Altered functional capacity of virtually all types of immune cells has been 
described in vitamin A deficiency. With HIV infection there is alteration in T-cell 
subsets and dysregulation of B lymphocytes. This study will assess the 
prevalence of vitamin A deficiency and the impact of vitamin A supplementation 
in HIV infected pregnant females. 
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1.2 HUMAN IMMUNODEFICIENCY VIRUS AND ACQUIRED 
IMMUNODEFICIENCY SYNDROME: 
The impact that human immunodeficiency virus (HIV) and AIDS have had on the 
world is unparalleled in modern times. AIDS was first diagnosed in mid-1981 
when an unusual form of pneumocystis carinii pneumonia (PCP) and Kaposi 
sarcoma were reported in young, previously healthy homosexual men. The 
pandemic is particularly devastating in sub-Saharan Africa. Over five million 
people in South Africa are expected to be HIV positive by the turn of the century 
and the epidemic is expected to peak in seven years time. HIV-1 infection in 
Kwa-Zulu Natal is increasing rapidly with 14.4%(1997) of child bearing women 
being seropositive(24). 
The World Health Organization (WHO) estimates that at least 30 million people 
are infected worldwide. There have been more than 1.4 million new infections in 
Africa every year since 1991. An estimated 90% of the world's HIV/AIDS burden 
is in resource poor settings and more than 70% of people requiring care are in 
sub-Saharan Africa(25 ). 
An estimated 26.8 million adults and 2.6 million children had become infected 
with HIV throughout the world since the start of the pandemic; of these, an 
estimated 5 million adults and 1.4 million children had died(26 ). 
Recent studies have addressed the timing of HIV transmission in neonates and 
suggest that the infection is more likely to occur as a peripartum event(27). 
HIV-1 is a member of the lentivirus subfamily of human retroviruses and the 
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etiologic agent of AIDS in the vast majority of cases throughout the world. HIV-2 
is another human retrovirus that causes AIDS and is endemic in parts of West 
Africa. It is closely related to simian immunodeficiency virus (SIV) and may be 
less pathogenic than HIV-1. HTLV-1 and HTLV-11 are also found with increased 
frequency in HIV-1 infected populations, particularly intravenous drug users(27). 
CD4+ lymphocytes and viral load have been unequivocally established as having 
clinical utility in management of HIV infected patients(28). Primary infection with 
HIV is followed by the development of detectable humeral and cellular immune 
responses to the virus and a prolonged period of clinical latency. Associated with 
the progression to AIDS is the rapid decline in normal T-cell function (switch to 
the T-helper type-2 response)(29). The polyclonal hypergammopathy, 
associated with 8-cell responses, are attributed to the T-helper type-2 responses 
(CD4+/CD29+ memory phenotype)(29,30). HIV activates resting 8-cells to 
produce various cytokines viz. TNF-alpha and IL-6. These cytokines have been 
shown to increase viral replication by acting on the Nf-KB-like L TR (long terminal 
repeats) sequences of the viral genome (30,31,32). Apoptosis appears to 
account for the progressive loss of T cells in infected individuals who develop 
AIDS irrespective of whether they bear the integrated proviral genome. Cells 
from long-term nonprogressors undergo a decreased level of apoptosis 
compared with those from patients with AIDS(33). 
Patients with HIV infection have been documented to have symptoms compatible 
with adrenal insufficiency(34) and symptoms occur in this setting with multiple 
opportunistic infections and profound wasting. Weight loss, often profound in 
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magnitude, is an almost universal feature of HIV infection, and patients may lose 
30 to 50% of their body mass before succumbing to the disease. Weight loss 
can be caused by five mechanisms: inadequate dietary intake, reduced intestinal 
absorption, abnormal utilization, increased excretion of nutrients, and increased 
host requirements. Weight loss contributes to an accelerated, downhill course; it 
can also be used to predict the time of death in patients with HIV infection. It has 
been suggested that reversal of weight loss in HIV-infected patients could repair 
the immunologic abnormalities caused by the wasting process, independent of 
those induced by the viral infection(35). 
Infection with the human immunodeficiency virus has been associated with the 
dysfunction of both T-and 8-cell activities soon after the primary viraemia. A slow 
replicating virus can be the more pathogenic type(36). Most paediatric HIV 
infection occurs in the perinatal period, when immunologic immaturity and 
antigenic naivete is well recognised(37). 
CD30 triggering may play an important role in promoting HIV replication(38). A 
rise in virus production then occurs concomitant with the onset of symptoms and 
eventually AIDS. Characteristics of long-term survivors include low infectious 
virus load, a less cytopathic HIV strain, no enhancing antibodies, TH1 
cell response greater than TH2 cell response and strong CD8+ cell antiviral 
response(39). 
The social and biologic consequences of HIV disease are greater in females. 
Women are more likely than men to rely on clinic care or to need drug 
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rehabilitation services. Several gynaecologic infections have been reported to 
have their natural course modified by HIV infection. Pelvic inflammatory 
disease(PID) has been noted to appear with less leucocytosis, but with more 
abscesses and a greater need for surgical intervention. Vaginal candidiasis is a 
common gynaecologic infection in HIV-infected women, and it has been 
commonly noted in those with normal CD4 counts, prior to the appearance of 
either oral or oesophageal candidiasis. HIV-1 seropositive pregnant women 
develop high rates of genital ulcer disease, genital warts, positive syphilis 
serology and stillbirths(40). HIV-1 seropositive women had significantly lower 
birthweight and with premature neonates. Factors that have been identified as 
possible risk factors for HIV mother-to-child transmission include impaired 
maternal clinical and immunological status, HIV seroconversion during 
pregnancy, shortened duration of pregnancy, vaginal delivery, prolonged or 
complicated labour and breast-feeding( 41 ). Pregnant women with CD4 counts < 
30% have higher risk of preterm delivery and postpartum endometritis is more 
common in HIV-1 infected women. More HIV seropositive pregnant women have 
raised temperatures on admission to the labour ward compared to the HIV 
negative women(42). Haematological parameters were abnormal in seropositive 
women and these did not progress over the course of pregnancy. At delivery 
seropositive women were more likely to receive antibiotics and have episiotomy 
although the obstetric outcome was unaffected. Seropositive women admitting to 
drug use had a significant increase in absolute lymphocyte count at delivery. 
Seropositive mothers were more likely to have sexually transmitted disease and 
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medical complications during pregnancy(43). In asymptomatic HIV infection, 
changes in the absolute levels of CD4 and CD8 lymphocyte counts were 
primarily related to changes in the other components of the white cell count. 
Pregnancy itself had no adverse effect on immunological markers in HIV infected 
individuals(44). 
In newborns the absence of the env-specific TH activity places them at risk for 
infection(45).The presence of immunologic abnormalities shortly after birth, 
confirms that HIV-1 may affect the immune system even during intrauterine 
life(46). Most of the HIV-1 infected babies showed early abnormalities in humeral 
and cellular immunity, hypergammaglobulinaemia, low percentage of CD4 
circulating lymphocytes and increased spontaneous in vitro immunoglobulin 
production. These changes were persistent in the HIV-1 infected children, but 
sporadic in those uninfected and immunological abnormalities were frequently 
found before clinical symptoms occurred(47). 
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1.3 B LYMPHOCYTES / B CELLS 
Lymphocytes are generated throughout human life though in gradually easing 
numbers. They play a dynamic role in the inflammatory response and the 
production of antibodies (48). In birds, 8 cells originate in a specialized organ 
called the Bursa of Fabricius, while in mammals 8-cell development occurs in the 
bone marrow. Each 8 cell bears a unique receptor and undergoes gene 
rearrangement which leads to the production of immunoglobulin. Each 
mammalian 8 cell produces only one heavy chain and one light chain, and 
thus bears receptors of a single specificity. A large and diverse repertoire of 8-
cell receptors is generated during the early phases of 8-cell development. The 
expression of antigen receptors on the surface of the 8 lymphocyte marks a 
major watershed in its differentiation(48). The binding of antigen to surface 
immunoglobulin early in development leads to inactivation or loss of the 
8 cell. 8 cells develop from progenitor cells in the bone marrow and rearrange 
their immunoglobulin genes to produce a receptor with unique antigen specificity. 
No surface immunoglobulin can be expressed until gene rearrangement is 
completed. This process is independent of the antigens in the environment, but it 
is however dependent on interactions with bone marrow stromal cells. Immature 
8 cells expressing surface immunoglobulin interact with antigens in 
their environment; if they encounter antigen they are rendered tolerant. These 
changes occur in the bone marrow, from which immature B cells emerge into 
the peripheral lymphocyte pool. Immature B cells differentiate within few days 
into mature B cells expressing surface lgM and lgD(48). The B cell can be 
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activated by encounter with antigen in a lymphoid organ and then respond by 
proliferating and differentiating into the last phase of the 8-cell life span. This is 
the antibody-secreting plasma cell, which may remain in the lymphoid organ but 
more usually migrates to the bone marrow. The successive stages of 8-cell 
differentiation are marked by the successive steps in the rearrangement of the 
immunoglobulin genes. Differentiation can be assessed on the basis of CDS 
expression and production of polyspecific lg(49). CDS+ B cells are strongly 
associated with autoimmune disorders and also in the rejection of HLA-DR and 
DQ compatible bone marrow graft. CDS+ B cells play a role in natural immunity 
in humans(SO). 
CD23 is also involved in 8-cell growth, pro-thymocyte maturation, myeloid 
precursor proliferation, inhibition of macrophage migration and antigen 
presentation(51 ). 
Tallon et al reported that haemodilution in pregnancy could be the cause for 
decrease in absolute lymphocyte counts of T and B cells in the third trimester of 
pregnancy(S2). As the plasma volume returns to normal post partum these cells 
return to normal numbers. 
Maclean et al reported that immunoglobulin production from peripheral blood 
was elevated in normal pregnancy and spontaneous abortion(S3). This group of 
workers were not certain as to whether the increase was as a result of increase 
in B cell numbers or increased production of immunoglobulin. B cell activation 
was also noted in some cases of spontaneous abortion. 
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Maclean et al found in normal pregnancy there is an increase in immunological 
potential of T and B lymphocytes without an increase in activity(54). 
Dodson et al found that T and B cell numbers were well within normal limits 
throughout gestation and the values were not significantly different from the 
normal non pregnant control women(SS). 
It was also confirmed in another study that B cell counts did not alter in early 
pregnancy( unpublished). 
Strelkauskas et al reported altered blood levels of T and B lymphocytes in the 
first half of human pregnancy(56). All their subjects showed an inversion of T 
and B cell levels in early pregnancy. They concluded that 8-cell levels 
(measured by surface immunoglobulin or surface antigen) were increased. 
Baines et al reported that gravid females show no increase or 
decrease in circulating thymus-derived or bone-marrow derived lymphocyte 
levels during the first eight months of pregnancy(57). 
Scott et al reported that the mean number of B cells is increased during 
gestation(58). 
HIV infected individuals, in addition to the depletion of CD4+ T cells, exhibit 
abnormalities in the 8-cell limb of the immune response and some are secondary 
to T-cell deficiency, while others are T-cell independent. B lymphocytes are not 
directly infected by HIV(59), although their function in HIV infection is severely 
impaired. The majority of AIDS patients exhibit polyclonal B-cell activation with 
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spontaneous 8-cell proliferation, increased lg secretion, and 
hypergammaglobulinaemia, suggesting chronic activation. These activated B 
cells are specific for HIV epitopes. In addition to spontaneous 8-cell 
hyperactivity, B cells from infected patients exhibit an intrinsic defect in antigen­
and mitogen-induced responses at all stages of infection(27). IL-6 is a critical 
factor in the terminal differentiation of activated B cells. It has been shown that 
exposure of normal PBL to HIV whole-virus preparation induces IL-6 production 
in vitro, predominantly by monocytes and that IL-6 induces HIV expression in 
infected monocytes, in synergy with other cytokines. Monocytes and T cells 
contribute to the secretion of IL-6, which plays an important role in the 
pathogenesis of B-cell activation in HIV infection. B cells themselves secrete 
TNF--a and IL-6 when activated and spontaneously activated B cells from HIV­
infected individuals secrete TNF-a and IL-6 which can induce HIV expression in 
chronically infected monocyte lines. The high frequency of 8-cell lymphomas in 
patients with AIDS is another manifestation of B-cell dysregulation(27). CD30+ 
CD4+ T cells exhibit significantly greater helper activity of B cell lg production 
than CD30-CD4+ T cells. CD30+ T cells exhibit potent helper activity for PWM­
driven B cell differentiation(60). B cell activation by most antigens requires 
binding of the antigen by the 8-cell surface immunoglobulin and interaction with 
antigen-specific helper T cells(61 ). These helper T cells induce a phase of 
vigorous 8-cell proliferation, after which the clonally-expanded progeny of naive 
B cells differentiate into either antibody-secreting or memory B cells. During the 
differentiation of activated B cells, several changes occur in the antibody 
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molecule. The number of B cells that express CD23 nearly doubles between 
infancy and adulthood(62). Retroviruses can induce autoimmunity, including 
polyclonal 8-cell activation, cytokine dysregulation, and molecular mimicry(59). 
1.4 HLA-DR (12) ANTIGENS 
The highly polymorphic cell surface structures involved in this system were 
initially identified in mice where they became known as the major 
histocompatibility complex (MHC) . Later, the human equivalent of the MHC, 
known as the human leucocyte antigen (HLA) system, was identified and found 
on chromosome 6 (63). Three classes of molecule, denoted I, II, and Ill, have 
been identified in the MHCs of both mouse and man. There are multiple Class I 
loci but the classical transplantation antigens fall into three positions termed H-
2K, H-2D and H-2L in the mouse and HLA-A, HLA-8 and HLA-C in man. The 
Class II genes, encoded in the A and E regions of the mouse MHC and the HLA­
D region of man, are now known to correspond directly to the immune 
response(lr) genes known to control responses to different antigens(63). Class I 
gene products are primarily recognized by cytotoxic T cells. Class II gene 
products, often called la (immune associated antigens), are primarily involved in 
the activation of helper T cells. Human HLA-DR (la) antigens were initially 
detected and studied using alloantisera, then heteroantisera and finally 
monoclonal antibodies. Originally, HLA -DR antigens were believed to be 
present exclusively on 8 cells but they were subsequently discovered on antigen 
presenting cells (monocytes, macrophages). HLA-DR antigens are widely 
distributed on haematopoietic cells and are even expressed on some non­
haematopoietic cells, especially in certain pathologic conditions(63). HLA-DR 
antigens are expressed in the earliest stages of haematolymphoid cell 
development. They are expressed throughout 8 cell ontogeny until the plasma 
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cell ( secretory) stage when they are lost. They are also present on 
haematopoietic progenitors and granulocyte, monocyte, erythroid and 
megakaryocytic precursors. HLA-DR antigens are expressed on myeloblasts but 
lost during maturation to the promyelocyte stage(64). Similarly, they are 
expressed on proerythroblasts and megakaryocytes but are absent from 
erythrocytes beyond the basophilic normoblast stage and platelets. HLA-DR 
antigens are present throughout monocyte/macrophage differentiation. HLA-DR 
are expressed at the earliest stages of T cell ontogeny but are quickly lost. The 
vast majority of thymocytes and mature peripheral and circulating lymphoid 
tissue T cells are HLA-DR negative. In vitro and in vivo activated T cells express 
HLA-DR antigens. HLA-DR antigens are expressed on the vast majority of B cell 
neoplasms(64 ). B cell neoplasms that are HLA-DR negative are those 
undergoing plasma cell differentiation. HLA-DR antigens have also been 
described in a variety of nonhaematopoietic neoplasms such as malignant 
melanomas. 
Maclean et al reported in normal pregnancy there was no activation of the 
immune system as noted by the activation marker (la)(54) . Moore et al
found the activation marker (la) percentages and absolute numbers were similar 
in normal and pre-eclamptic pregnancies(65). 
Haynes et al reported that MHC class I and class II genes play a major role in 
determining the specificity of T and B cell antiviral immune responses(66). There 
is considerable interest in searching for an HLA association with long-term 
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survivors of HIV infection(67). 
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1.5 NATURAL KILLER CELLS 
A great deal of work regarding the study of Natural Killer (NK) activity has 
occurred over the last decade. The cell type identified as being responsible 
for this activity was a large granular lymphocyte (LGL). This form of lymphocyte 
has a high cytoplasm to nuclear ratio and displays distinct azurophilic granules. 
It should be noted that, as with other cell types, heterogeneity exists amongst the 
NK cell population with some NK cells not displaying the distinct LGL morphology 
during certain states of differentiation and/or activation. In studies performed 
over the last decade on spontaneous cell-mediated cytotoxicity, it has become 
clear that natural effectors comprise a variety of cell types which mediate both 
distinct cytolytic capacities as well as non-cytolytic functions. These capacities 
include not only NK activity, but also lymphokine-activated killer (LAK) activity 
and antibody-dependent cellular cytotoxicity (ADCC). Natural Killer cells work 
synergistically with 8 cells. This interaction has been demonstrated to decrease 
viral load in severe combined immunodeficiency (SCIO) in mice(68). Natural 
Killer cells are effectors of the natural immune system and provide the first line of 
defense against infection(69). Spontaneous non-major histocompatibility 
complex (MHC) restricted killing can be mediated by NK cells(70), 
by certain activated T-cells, and by cells in the monocyte/macrophage series. NK 
cells are present in high numbers at birth, when they constitute about 20% of 
circulating lymphocytes. After an initial decline during the first year of life, the 
percentage of NK cells slowly increases to adult levels. NK cells in cord blood are 
less active than those in adults; this may reflect their immaturity or the absence 
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of cytokines necessary for full NK activation(62). HIV positive children may have 
increased natural killer cells which is associated with a decreased CD4 count. 
Unlike adults an increase in these cells might be noted in early stages of HIV 
infection(71 ). Extensive research is under way worldwide to determine the role 
of interferons and interleukins in the regulation of the NK cell. They 
mediate cytolytic reactions that do not require expression of class II MHC 
molecules on the target cells. Certain T lymphocytes which are either a/� 
positive or y/o positive may express, particularly upon activation, a cytolytic 
activity that resembles that of NK cells. These T lymphocytes should not be 
termed NK cells. They could be termed either T lymphocytes displaying "NK­
like" activity or "non-MHC requiring" cytolysis. It is known that the recognition of 
target cells by NK cells will lead to target cell destruction. Propodium iodide was 
used to stain target cells killed by NK cells and it was found that NK cell 
cytotoxicity was not cell cycle specific(72). 
The activity of NK cells against infectious diseases has received less attention, 
although in recent years increasing evidence has emerged that NK cells are 
involved in defence against such forms of disease(?O). Cells with NK activity 
have been able to inhibit microbial colonization and growth, including intracellular 
and extracellular parasites, fungi, and a wide variety of viral infections. The role 
played by NKcells in host defences against bacterial infections has remained 
unclear. NK cells may be of major significance in viral infections because of the 
ability of viruses to alter cell metabolism and architecture, and also because 
viruses are potent inducers of interferons (IFNs), which augment NK cell 
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cytotoxicity and proliferation(70). The augmented NK cell response that occurs 
after viral infection is the result of two phenomena: the activation of NK cells to a 
higher state of cytotoxicity and the proliferation of NK cells, which results in an 
increase in NK cell number. Natural killer cells are dependent on a population of 
HLA-DR+ accessory cells in viral infection(73). Depletion of HLA-DR positive 
cells from peripheral blood lymphocytes depletes NK activity(74). 
The most profound changes in LGL populations in pregnancy occur at the 
maternal/fetal interface in the uterus. NK activity has been measured and 
compared to blood samples from pregnant and non-pregnant women and from 
men. Blood NK activity was found to be lower in women than in men, and to fall 
significantly in non-pregnant women in the periovulatory period. In pregnancy, 
NK activity of blood lymphocytes is decreased from 16 weeks of pregnancy 
onwards. NK activity returns to normal (control) levels between 9 and 40 weeks 
post-partum. Antibody-dependent cell-mediated cytotoxic (ADCC) activity 
decreases during pregnancy and returns to slightly above normal (control) levels 
post-partum(70). The mechanism for the reduction in peripheral NK activity in 
pregnancy is not clear. 
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CHAPTER 2 
AIMS AND OBJECTIVES 
2.1 Purpose of Study 
To evaluate the immunological basis for the use of vitamin A as an intervention to 
modulate B cells, natural killer cell counts and the activation marker (12) in HIV 
seropositive pregnant women in developing countries. The effects of vitamin A 
on the T lymphocytes was the research focus of another researcher. 
2.2 Hypothesis 
Vitamin A and beta-carotene supplementation will modulate the immune 
responses in HIV infected pregnant women, either by enhancing 8-lymphocyte 
production and differentiation, by stimulating the production of natural killer cells 
or by altering immune activation. 
2.3 Primary Objective 
To assess the effects of Vitamin A and Beta-Carotene on natural killer cells and 
B cells. 
Specific Objectives:-
(a) To evaluate 8 cell percentages and absolute numbers.
(b) To evaluate natural killer cell percentages and absolute numbers.
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2.4 Secondary Objectives 
To assess the effects of Vitamin A on haematological parameters and activation 
status of lymphocytes. 
Specific Objectives:-
(a) To evaluate the following parameters (haemoglobin,
haematocrit, white cell counts, platelets and lymphocytes).
(b) To evaluate 12 (HLA-DR), the activation marker.
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Subjects were recruited from pregnant women presenting to the ante-natal clinic 
(ANG), King Edward VIII Hospital (KEH). These subjects were part of a 
randomised, double blind, placebo controlled intervention trial using vitamin A. 
Recruitment of Study Subjects 
Routine HIV screening was conducted at King Edward VIII Hospital-Ante Natal 
Clinic ( KEH-ANG) and was preceded by pre-test counselling. When women 
returned for their results those testing positive were given post-test counselling. 
Those positive women who were between 28-32 weeks gestation had the study 
objectives and design explained to them and were asked for written informed 
consent to participate in the trial. Women were then randomly allocated to 
receive daily vitamin A (retinol palmitate and beta-carotene) or placebo. 
Sampling 
Sample size was determined at 39 in order to obtain test significance level alpha 
0.05 with 80% power in order to detect 5-7% change in numbers of absolute 
lymphocyte and Natural Killer cells. The larger numbers recruited initially allowed 
for the subsequent sub-sampling at the various time intervals (not all patients 
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recruited had the tests repeated at each interval and allowance was made for 
drop-outs. 
For the purposes of this study the first 208 patients recruited to the intervention 
trial were evaluated. Of the 208 patients intially recruited 103 were in the vitamin 
A group and 105 were in the placebo group. Sampling was performed on 
enrollment, at delivery, 1 week, and 3 months post delivery. 
Exclusion Criteria 
Any woman who did not have a fixed, traceable address at which she would 
remain for 15 months. 
Ethical Considerations 
It has been well documented that vitamin A is a potential teratogen at daily doses 
of 25 000 IU. The Teratology Society has recommended that a daily dose of 
8000 IU of vitamin A (as retinol esters) should be considered as the maximum 
dose to be given during pregnancy. The subjects were given 5 000 IU of retinol 
palmitate and it was given in the last trimester of pregnancy to minimise any 
possibility of embryotoxic effects. Since beta-carotene has not been associated 
with any embryotoxic effects an additional 30 mg of beta-carotene was included 
together with the 5000 IU of retinyl palmitate. 
Ethical Approval 
Ethical approval was granted by the Ethics Committee for the application of the 
randomised trial on vitamin A which was submitted by the Department of 
Paediatrics and Child Health to the Ethics Committee, University of Natal. 
Ethical approval for this study was granted by the Ethics Committee. 
The reference number is H192/97. 
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3.2 METHODS 
3.2.1 Vitamin A Concentrations 
Vitamin A - a daily tablet containing 5000 IU of retinal palmitate and 30mg of 
beta-carotene was administered from time of entry to study (28-32 weeks) until 
onset of labour. This was followed by a further 200,000 IU one day after delivery. 
Blood was taken for vitamin A concentration on entry to the study and one 
month later to test the effect of supplementation. The serum was separated and 
stored at -70 °C until analysis. Precautions were taken to protect the serum from 
light during separation, storage and analysis as vitamin A is sensitive to photo 
degradation. Vitamin A (serum retinal ) was measured by normal phase high 
pressure liquid chromatography using fluorescence detection. The method used 
was a modification of a previously reported method that had been successfully 
set up in our analytical unit and had been used in several studies (attached to a 
programmable fluorescence detector - HP 1046)(75). This method has been 
validated by using standard reference material for retinal (SAM 968a) from the 
National Institute for Standards and Technology (Gaithersburg, MD). All samples 
were analysed in duplicate within six months of collection and the technician was 
blinded as to the treatment groups. 
Retinal levels for the study was done in collaboration with the Analytical Unit, 
Department of Physiology, by Mrs Inga Elson in the Medical School, University of 
Natal. 
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3.2.2 Monoclonal Antibodies 
Monoclonal antibodies are produced by clones of plasma cells. Antibodies from 
a given clone are immunochemically identical and react with a specific epitope on 
the antigen against which they are raised(76). 
In our study CD19 was used as a marker for B lymphocytes, CD56 as the marker 
for natural killer cells and 12 (HLA-DR) as an activation marker. 
CD19 / B4 Monoclonal Antibody 
CD19 is a murine monoclonal antibody reagent. In conjunction with a fluorescent 
label, it is used to identify and enumerate the percentage of CD19 positive B 
lymphocytes in whole blood or mononuclear cell preparations by flow 
cytometry or fluorescence microscopy. This antigen is 
expressed on all normal B lymphocytes, follows the la antigen in B cell ontogeny, 
and is only lost prior to plasma cell differentiation(??). The CD19 antigen is 
present on all B cells isolated from lymphoid organs and on approximately 5% of 
normal adult bone marrow cells. The immunoglobulin chain composition of CD19 
is mouse lgG1 heavy and kappa light chains. 
CD56/NKH-1 Monoclonal Antibody 
CD56 (NKH-1) defines a human Natural Killer cell antigen, with a molecular 
weight of 200-220 Kd(78). It is expressed on a subpopulation of peripheral blood 
large granular lymphocytes (LGL) which demonstrate Natural Killer activity. More 
than 95% of cells capable of mediating spontaneous non-MHC restricted 
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cytotoxicity in peripheral blood are contained within the 10-12% of peripheral 
blood mononuclear cells (PBMC) that express CD56 (NKH-1 )(78). 20-
25% of CD56 positive cells co-express CD3 and T cell receptor gene products. 
CD56 (NKH-1) is not expressed on other T cell populations, B cells, monocytes, 
granulocytes and erythrocytes. The CD56 (NKH-1) antibody helps detect and 
enumerate Natural Killer cells in normal and disease states. Natural Killer cells 
also commonly express the cell surface marker CD16(70). The immunoglobulin 
chain composition of CD56/NKH-1 is mouse lgG1 heavy and kappa light chains. 
HLA-DR/12 Monoclonal Antibody 
The 12 antigen is an HLA-D/DR related la-like antigen with a estimated molecular 
weight of 29-34 Kd. It is present on normal B cells, monocytes, and activated T 
lymphocytes(64). It is not present on progranulocytes or resting 
T cells. The immunoglobulin chain composition of HLA-DR/12 is mouse lgG2a 
heavy and kappa light chains. Because dual markers were not used to identify 




Flowcytometry is a modern method of studying cells. Various techniques 
could be employed to ascertain multiple physical or biological properties of a 
cell. Quantitative cell analysis, at the single-cell level, is possible through flow­
cytometry. Cell populations and sub-populations in a specimen can be 
determined by the number and type of cell surface antigens, or by measured 
internal parameters(79). Samples for flowcytometry were processed on a Coulter 
Epics Profile II flowcytometer. (Coulter Electronics-Hialeah, Florida, U.S.A.). The 
instrument was programmed to measure forward scatter (FS), log side scatter 
(LSS), and log fluorescence. 
Alignment and Sample Preparation 
Flow Check (Coulter Electronics-Hialeah, Florida, U.S.A.) alignment reagent was 
used. lmmunobrite beads (Coulter Electronics-Hialeah Florida,U.S.A.) were 
used to calibrate the instrument. A normal control was prepared and 
analysed (this sample was collected from a normal person who had not been on 
any medication or suffered from any ailment affecting the immune system 
fourteen days prior to sample collection). This sample was prepared exactly like 
the study patients' test samples of the day. The normal control lymphocyte zone 
was gated to give a yield of at least 96% of total cells analysed. Cursors were 
set on histograms to differentiate between positive and negative zones. Samples 
from the study patients were collected and prepared as follows:-
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1. 5mls of whole blood was collected in EDTA anticoagulant.
2. All tests were set up within one hour of collection.
3. 1 00ul of a well mixed sample was aliquoted into 75 x 12mm plastic
tubes(polyurethane ).
4. Respective monoclonal antibodies and isotypic controls
were added.
5. The samples were vortexed and incubated at
room temperature in the dark for 30 minutes.
The samples were passed through a Coulter Workstation - Q-Prep.(Coulter 
Epics Immunology Workstation - Hialeah, Florida, U.S.A.). This instrument has a 
Lysing (reagent A), stabilising (reagent 8) and fixing agent (reagent C). 
Reagent A - (formic acid) - 600ul 
Reagent 8 - (sodium chloride, sodium sulphate and sodium 
carbonate)- 265ul 
Reagent C - (paraformaldehyde) - 100ul 
The reagents were dispensed automatically (the amounts as indicated above) 
with vigorous mixing at intervals in a 35 second cycle in the Coulter workstation. 
After preparation in the Q-Prep workstation the control and test samples were 
analysed on the flowcytometer. Gated cells were expressed as a percentage on 
the positive analysis histograms. This was later converted to absolute numbers 
using the full blood count parameters. 
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Quality Control 
Fluorescent microspheres were used to align the flowcytometer laser and for 
calibration. To control for non-specific binding isotypic controls were used. 
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3.3 Data Management and Statistical Analysis 
MRC-Biostatistician was consulted. The following software packages were used: 
EPI-INFO6 for data capture and SAS Version 6.12 was used for statistical 
analysis. Statistical analysis consisted of univariate analysis. Univariate analysis 
depended on type of data (eg Chi-square, T-test). 
Descriptive statistics consisting of means and confidence intervals were 
calculated by group and time for each of the variables of interest. Variables were 
generally normally distributed. Parameters analysed were haemoglobin, 
platelets, white cell counts, absolute lymphocyte counts, B lymphocyte 
percentage and absolute counts, Natural Killer cell percentage and absolute 
counts, activation marker (12), percentage and absolute counts and retinol levels. 
Baseline parameters were compared between the placebo and vitamin A groups 
using Student's paired and unpaired t-test. The difference between the three 
month measurement and the baseline was calculated to assess the changes 
over time. The two groups were then compared with respect to this change 
using a unpaired t-test. The difference from baseline to 3 months post-delivery 
within each group was assessed using a paired t-test. A significance level of 
0.05 was used. 
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3.2.4 Haematological Parameters 
The patients peripheral blood samples were analysed for - haemoglobin, 
haematocrit, platelets, white cells, and absolute lymphocyte counts. These 
parameters were evaluated at each sampling interval on the Coulter Stks. Model 




The results are presented as follows: -
(1) Baseline Values
Figure 1 to Figure 4. 
(2) Trends










BASELINE HAEMOGLOBIN VALUES 
<8 >=8 < 9 
5 23 
>=9 < 10 >=10 < 11 >=11 < 11.5 >=11.5 
40 68 30 42 
Haemoglobin g/dl 
Mean = 10.57g/dl Range= 7.6 - 13.5 (n=208) 
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Figure 2 
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BASELINE WHITE CELL COUNTS 
> 5 <=10 > 10 <=14 > 14
11 164 31 2
White Cell Count x 109 /I
Mean = 7.86 X 109 /I Range = 4.0 - 16.7 (n=208) 
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Figure 4 
BASELINE LYMPHOCYTE COUNTS 
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Figure 5 














V p V p V p V p 
8 
Baseline Delivery 1Week/PP 3Month/PP 
Study Intervals V= Vitamin A 
P= Placebo 
• Vitamin A - significant increase between baseline and 3 months p < 0.0000
• Vitamin A - significant increase between delivery and 1 week p < 0.0017
• Vitamin A - significant increase between delivery and 3 months p < 0.0000
• Placebo - significant increase between baseline and delivery p < 0.0209
• Placebo - significant increase between baseline and 3 months p < 0.0000
















V p V p 
Delivery 1Week/PP 
Study Intervals 
• Vitamin A - significant increase between baseline and 3 months p < 0.0121
• Vitamin A - significant increase between delivery and 1 week p < 0.0389
• Vitamin A - significant increase between delivery and 3 months p < 0.0029
• Placebo - significant increase between baseline and 3 months p < 0.0000
• Placebo - significant increase between delivery and 3 months p < 0.0001






V= Vitamin A 
P= Placebo 
Figure 7 













V p V p V p V p 
0 
Baseline Delivery 1Week/PP 3Month/PP 
Study Intervals V = Vitamin A 
P = Placebo 
• Vitamin A - significant increase between baseline 1 week p < 0.0000
• Vitamin A - significant increase between delivery and 1 week p < 0.0007
• Vitamin A - significant decrease between 1 week and 3 months p < 0.0147
• Placebo - significant increase between baseline and 1 week p < 0.0000
• Placebo - significant increase between baseline and 3 month p < 0.0224
• Placebo - significant increase between delivery and 1 week p < 0.0000
• Placebo - significant increase delivery and 3 months p < 0.0010
• Placebo - significant decrease between 1 week and 3 months p < 0.0027
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Figure 8 
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o.,__ ________________________ ___:_ ______ ___, 
Baseline Delivery 1Week/PP 3Month/PP 
Study Intervals 
• Vitamin A - significant decrease between baseline and 1 week p < 0.0079
• Vitamin A - significant decrease between baseline and 3 months p < 0.0000
• Vitamin A - significant decrease between delivery and 1 week p < 0.0093
• Vitamin A - significant decrease between delivery and 3 months p < 0.0000
• Vitamin A - significant decrease between 1 week and 3 months p < 0.0186
• Placebo - significant decrease between baseline and 3 months p < 0.0000
• Placebo - significant decrease between delivery and 1 week p, 0.0149
• Placebo - significant decrease between delivery and 3 months p < 0.0000
• Placebo - significant decrease between 1 week and 3 months p < 0.0044
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0.8
Baseline Delivery 1Week/PP 3Month/PP 
Study Intervals V= Vitamin A 
P = Placebo 
• Vitamin A - significant increase between baseline and 3 months p < 0.0285
• Vitamin A - significant increase between baseline and 1 week p < 0.0006
• Vitamin A - significant increase between delivery and 1 week p < 0.0034
• Vitamin A - significant increase between delivery and 3 month p < 0.0077
• Placebo - significant increase between baseline and 3 month p < 0.0429
• Placebo - significant increase between baseline and 1 week p < 0.0001
• Placebo - significant increase between delivery and 1 week p < 0.0223
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Figure 10 
B CELLS - CD19 - TRENDS 
15 





V p V p V p V p 
0 
Baseline Delivery 1Week/PP 3Month/PP 
Study Intervals 
V=Vitamin A 
P = Placebo 
• Vitamin A - significant decrease between baseline and 1 week p < 0.0024
• Vitamin A - significant decrease between delivery and 1 week p < 0.0157
• Vitamin A - significant increase between 1 week and 3 months p < 0.0016
• Placebo - significant decrease between baseline and 1 week p < 0.0005
• Placebo - significant decrease between delivery and 1 week p <0.0036
• Placebo - significant increase between 1 week and 3 months p <0.0025
.J4 
Figure 11 
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0 
Baseline Delivery 1Week/PP 
Study Intervals 
• Vitamin A - significant increase between baseline and 3 months p < 0.0459
• Vitamin A - significant increase between 1 week and 3 months p < 0.0464
• Placebo - significant increase between baseline an 3 months p < 0.0111





V = Vitamin A 
P = Placebo 
Figure 12 
NATURAL KILLER CELLS - CD56 -TRENDS 
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V p V p V p V p 
0 
Baseline Delivery 1Week/PP 3Month/PP 
V= Vitamin A 
Study Intervals P = Placebo 
• Vitamin A - significant increase between baseline and 1 week p < 0.0215
• Vitamin A - significant increase between delivery and 1 week p < 0.0325
• Vitamin A - significant decrease between 1 week and 3 months p < 0.0062
• Placebo - significant increase between delivery and 1 week p < 0.0478
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Figure 13 
















V p V p V p V p 
0 
Baseline Delivery 1Week/PP 3Month/PP 
V = Vitamin A 
Study Intervals P = Placebo 
• Vitamin A - significant increase between baseline and 1 week p < 0.0170
• Vitamin A - significant increase between delivery and 1 week p < 0.0004
• Vitamin A - significant increase between delivery and 3 month p < 0.0133
• Vitamin A - significant decrease between and 1 week and 3 month p < 0.0054
• Placebo - significant increase between baseline and 1 week p < 0.0088
• Placebo - significant increase between delivery and 1 week p < 0.0072
Figure 14 
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Baseline Delivery 1Week/PP 3Month/PP 
Study Intervals V
= Vitamin A 
P= Placebo 
• Vitamin A - no significant changes noted
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0 
Baseline Delivery lWeek/PP 
Study Intervals 
• Vitamin A - significant increase between delivery and 1 week p < 0.0452





V = Vitamin A 




These were assessed when study subjects were enrolled. The following 
parameters were tested - haemoglobin, haematocrit, platelets, white cells, 
absolute lymphocyte counts, B lymphocyte percentages and absolute counts, 
Natural killer cell percentages and absolute counts and the activation marker 
percentages and absolute counts. No differences were present at baseline 
between the placebo and vitamin A treated group (Table 1 ). 
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Table 1 
Baseline parameters in Vitamin A and Placebo HIV(+) Black Mothers. 
VITAMIN A PLACEBO 
n 103 105 
Hb G/dl 10.51 10.63 
(10.26-10.76) (10.41-10.85) 
HCT 29.96 29.02 
% (26.89-31.03) (27.51-30.54) 
PLT 258.40 253.30 
X109/1 (243.39--273.37) (238.29-268.31) 
wee 7.80 7.92 
X109/I (7.41-8.19) (7.448.39) 
LYMPHS 1.77 1.71 
X109/1 (1.64-1.89) (1.60-1.81) 
CD56 10.42 10.15 
% (9.29-11.55) (9.11-11.19) 
CD56 0.20 0.18 
ABS (0.16-0.24) (0.16-0.21) 
X109/I 
CD19 10.26 10.87 
% (9.55-10.97) (10.17-11.56) 
CD19 0.18 0.19 
ABS (0.16-0.20) (0.17-0.20) 
X109/1 
12 32.13 33.03 
% (27.93-36.32) (29. 67-36.39) 
12 0.59 0.64 
ABS (0.50-0.69) (0.45-0.83) 
X109/I 
Results are presented as a Mean with (95% Confidence Intervals) 
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Baseline Parameters in HIV(+) Black Mothers 
Both groups were considered together for the purposes of describing our HIV(+) 
black African cohort. These were compared to reported parameters in HIV(-) 
normal pregnant females. 
Haemoglobin and Haematocrit 
In normal pregnancy, the maternal blood volume increases markedly 
(80,81,82,83). The blood volume at or very near term increases by 
approximately 45%. The degree of expansion varies considerably. In some 
women there is only a modest increase and in others the blood volume nearly 
doubles. The maternal blood volume starts to increase during the first trimester, 
and eventually plateaus out during the last several weeks of pregnancy. The 
increase in blood volume results from an increase in both plasma and 
erythrocytes. Although more plasma than erythrocytes is usually added to the 
maternal circulation, the increase in the volume of circulating erythrocytes is 
considerable. In spite of the augmented erythropoiesis, the concentration of 
haemoglobin, erythrocytes and the haematocrit commonly decrease during 
pregnancy. The normal range for haemoglobin in pregnancy is 11.0 - 14.0g/dl 
(84). In this study (see figure 1) the mean haemoglobin at baseline was 10.51 
g/dl (Cl=10.26-10.76) in the vitamin A group and 10.63g/dl (Cl=10.41 - 10.85) 
in the placebo group. The haemoglobin range was 7.6 - 13.5g/dl. Of the patients 
65.4% (136 out of 208) had haemoglobin levels of� 11.0g/dl. Five patients had 
haemoglobin levels of� 8.0g/dl. 
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Alger et al, reported that HIV+ patients had a significantly lower haemoglobin 
(10.6 ± 1.2g/dl) at recruitment than the HIV- patients (11.3 ± 1.3g/dl)(42). 
Various factors including poor dietary intake, lack of supplements during 
pregnancy, blood loss and infections may contribute to the anaemia. 
In this study the haematocrit values were proportional to their haemoglobin 
levels. The mean haematocrit levels were 29.96% (Cl=26,89 - 31.03) in the 
vitamin A group and 29.02% (Cl=27.51 - 30.54) in the placebo group. 
Platelets 
Conflicting reports have been made about platelet counts during pregnancy. 
Some early reports show increase in platelet counts and others show no 
significant change. Some more recent reports using modern automated 
technology show a progressive fall in pregnancy(85,86,87,88). Average platelet 
counts reported for normal pregnancy include 219 X 10
9/1 during 27 - 30 
weeks(89), 183.9 X 109/1 in the third trimester(85), and 284.18 X 109/1 during 26 -
30 weeks of pregnancy(86). In this study (see figure 2), the mean platelet count 
at baseline in the vitamin A group was 258.40 X 109/1 (Cl=243.39-273.37) and in 
the placebo 253.30 X 109/1 (Cl=238.29-268.31 ). Six patients had 
thrombocytopenia with counts <150 X10
9
/I, of whom 2 had counts of <100 X 
109/1. The reasons for the thrombocytopenia were not noted. Two patients had 
counts of >450 X 109/1. 
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Total White Cell Count 
Total leucocyte count rises early in gestation and remains elevated during 
pregnancy, with neutrophils accounting mainly for the increase(52,53,54,90,91 ). 
Moore et al established a mean leucocyte count of 8.55 ± 1.13 x109/1 in normal 
pregnant women between 29-39 weeks(65). Pitkin et al, reported leucocyte 
counts of 5.60-12.21 x 109/1 in the third trimester of pregnancy. Maclean et al
established a mean white cell count of 10.7 X109/I in the 28th week of pregnancy. 
In this study (see figure 3) the mean leucocyte counts at baseline was 7.86 x 
109/1 with a range of 4.0-16.7 X 109/1. Eleven out of 208 patients (5.2%) of our 
cohort had white cell counts <5.0 X 109/1. Two patients in the study had white 
cell counts of > 16 X 109/1. 
Lymphocytes 
The reports in the literature are conflicting. In normal pregnancy there is no 
change in the lymphocyte count (54,55,57,91,). Pitken et al and Johnstone et al 
found that absolute lymphocyte counts decline in pregnancy (90,92). Pitken et 
al, reported a lymphocyte range of 1.13-2.58 X 109/1 in the third trimester of 
pregnancy( 90). 
Maclean et al, reported a lymphocyte mean value of 1.8 X 109/1 at 28 weeks of 
gestation(54 ). Moore et al found a mean value of 1.57 X 109/1 at 29 - 39 weeks 
of pregnancy(65). In this study (see figure 4) the mean lymphocyte count ( X 
109/1) at baseline was 1.77(Cl=1.64-1.89) and 1.71(Cl=1.60-1.81) in the vitamin A 
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and placebo groups respectively. 
Lymphopenia was noted in 9.1 % (19 out of 208) with lymphocyte counts of 
>0.3�1.0 X109/1. Lymphocytosis of >3.5 X 109/1 was noted in 2 patients while the
remaining 187 patients (89.9%) had normal lymphocyte counts. 
B Cells 
Dodson et al reported that B cell counts in gravid women is normal throughout 
gestation(55). They reported a B cell count of 10% between 25-30 weeks of 
pregnancy. Strelkauskas et al found that B cell counts ( as measured by the 
presence of surface immunoglobulin or the presence of B cell surface antigens) 
were increased(56). Tallon et al established a B cell count of 9.4% and a 
decrease in the absolute count in the third trimester of normal pregnancy(52). 
In this study (see Table 1), the B cell (CD19) percentage was 10.26% (Cl=9.55 
10.97) and 10.87% (Cl=10.17 - 11.56) in the vitamin A and placebo groups 
respectively. The B cell mean absolute count (X109/I) was 0.18 (Cl=0.16-0.20) 
and 0.19 (Cl=0.17 - 0.20) in the vitamin A and placebo groups respectively. 
Natural Killer Cells 
Very limited research has been performed on Natural Killer cells using CD56 as a 
marker in this setting. 
In this study (see Table 1) the Natural Killer cell (CD56) mean percentage was 
10.42 (9.29 - 11.55) and 10.15% (CI=9.11 - 11.19) in the vitamin A and placebo 
groups respectively. The Natural Killer cell mean absolute count was 0.20 
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(Cl=0.16 - 0.24) and 0.18 (Cl=0.16 - 0.21) X 109/1 in the vitamin A and placebo 
groups respectively. 
Kuhnert et al reported a mean Natural Killer cell percentage of 14.0 ± 6.3% in 
non-pregnant females and 12.2 ± 5.4% in pregnant females in the third trimester 
of pregnancy(93). They also reported an absolute count 0,253 x 109/L in 
non-pregnancy and a count of 0.192 x 109/L in the third trimester of pregnancy. 
Activation Marker 
Moore et al concluded that the mean la ( activation marker) percentage in the 29-
39 weeks of normal pregnancy was 20.9% (65). Maclean et a/found that 
lymphocytes from pregnant women had increased potential rather than increased 
activity. This group of workers established that the value for la (activation 
marker) in the 28th week of pregnancy was 0.11 X 109/1 (54). In this study (see 
Table 1) the activation marker (12) mean percentages were 32.13 (CI=27.93 -
36.32) and 33.03%(Cl=29.67 - 36.39) in the vitamin A and placebo groups 
respectively. The activation marker mean absolute values were 0.59 (Cl=0.50 -
0.69) and 0.64 (Cl=0.45 - 0.83) X 10





Retinol levels at Baseline in the Vitamin A group and Placebo Group 
VITAMIN A PLACEBO 
Retinol 
Levels 37.5% 38.5% 
<20ug/dl (n=15) (n=20) 
Retinol 
Levels 50.0% 55.7% 
>20<40 (n=20) (n=29) 
ug/dl
Retinol 
Levels 12.5% 5.7% 
>40 (n=5) (n=3) 
ug/dl
Mean Retinol P-VALUE RANGE 
Levels 25.65 24.38 
ug/dl (21. 71-29.60) (21.80-26.97) 0.5758 7.8 -64.5 
The normal retinol level in non-pregnant and pregnant females is 
20-60ug/dl(94). Retinol levels for the two groups were comparable and there
was no significant differences noted (p = 0.5758). The mean retinol levels were 
25,65ug/dl (Cl=21.71 - 29.60) and 24.38ug/dl (Cl= 21.80 - 26.97) in the vitamin A 
and placebo groups respectively. The retinol range was 7.8 - 64.5ug/dl. 
In this cohort 92 patients had retinol levels measured (see Table 2). There were 
40 patients in the vitamin A group and and 52 patients in the placebo group. 
It was established that 15 patients (37.5%) in the vitamin A group and 20 
patients (38.5%) in the placebo group were deficient. In the vitamin A group 
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62,5% (25 out of 40) and 61,5% (32 out of 52) in the placebo group had normal 
retinal levelsln the patients with normal vitamin A levels >80% of the values were 
low normals (20 - 40ug/dl). 
Coutsoudis et al found that women attending the King Edward VIII hospital 
maternity service were not, a vitamin A deficient population(12). 
Another local study done at this hospital showed multiple nutritional deficiencies 
associated with decreased or inadequate immunity in HIV positive patients(95). 
In a study done in the United States mean vitamin A levels were lower in blacks 
than in Hispanics and whites(96). Pregnancy, HIV infection, low socioeconomic 
status and race may all be associated with vitamin A deficiency. 
Pregnant women may be at higher risk for vitamin A deficiency because of 
increased demands for vitamin A by the developing fetus. In HIV positive women 
vitamin A deficiency may occur as a result of many possible factors including low 
intake and malabsorption of vitamin A-rich foods, liver disease and abnormal 
urinary losses of vitamin A during infection(97). Stephensen et al also reported 
that patients with pneumonia and sepsis excrete significant amounts of retinal 
and retinal binding protein (RBP) in their urine, unlike healthy individuals who 
excrete only trace amounts(97). Therefore, the requirement for vitamin A is 
greatly increased during acute infections which might be related to the loss of 
retinal in the urine. A high prevalence of vitamin A deficiency has been 
demonstrated among HIV-infected adults(98). During infectious illnesses 
vitamins are utilised in greater amounts than in the normal state and therefore 
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body vitamin stores are depleted(98). The reasons proposed for the low levels 
in pregnancy were an increase in circulating blood volume, an inadequate 
dietary vitamin intake, an increase in renal vitamin clearance, fetal sequestration 
and an increase in vitamin catabolism and tissue retention. The rise was 
attributed to the end of the pregnancy as well as factors like oral contraceptives. 
Baker et al found that there was progressive decrease in retinol 
during pregnancy up to 28 weeks which starts early in pregnancy(99). In 
contrast, others found an increase in retinol levels during pregnancy(100, 101 ). 
Bruinse et al observed low retinol levels in pregnancy and a rapid significant 
increase in retinol levels within days after delivery(102). The reasons for the low 
levels in pregnancy were Baranowitz et al studied 84 HIV+ patients and found 
that the majority were deficient or had low normal serum carotene levels(100). 
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TRENDS NOTED AT VARIOUS INTERVALS OF STUDY 
Haemoglobin 
Haemoglobin levels at 3 months post partum are significantly increased for both 
groups (see figure 5). These probably reflect basal non-pregnancy values for 
the study individuals, and were similar in both groups. The placebo group 
showed an earlier increase in the haemoglobin level between baseline and 
delivery compared to the vitamin A group which increased between delivery and 
1 week post partum. Similar significant differences were noted within subjects 
between delivery and 1 week in the vitamin A group and between baseline and 
delivery in the placebo group. 
Alger et al, reported a modest increase in the haemoglobin values at delivery in 
the HIV+ patients(10.6-10.9g/dl). At delivery there was no difference between 
the infected and uninfected patients(42). Our study showed a similar modest 
increase between baseline and delivery in the vitamin A (10.51 ➔10.83g/dl) and 
(10.63 ➔ 11.12g/dl) in the placebo group. 
Haematocrit 
In parallel with haemoglobin levels seen the haematocrit trends in our 
study were also elevated at 3 months compared to baseline in the two groups 
(see figure 6). The groups were comparable at 3 months and were reverting to 
normal levels post partum. 
Pritchard et al reported that in normal pregnancy the haematocrit 
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returns to normal 6-7 days post partum(82). It is possible that vitamin A therapy 
may have contributed to earlier normalisation. The significance of this difference 
is uncertain. 
Platelets 
The groups were comparable at 3 months with no significant difference in their 
means (see figure 7). The higher platelet counts at 3 months probably reflect 
normal non pregnant values. The placebo group and the vitamin A group 
showed no significant change in pregnancy. The groups behaved similarly after 
delivery with a rise at 1 week and a subsequent fall at 3 months. 
Fenton et al found that platelet counts do not change during normal 
pregnancy(89). Cairns et al reported that there is a small decline in 
platelet counts throughout pregnancy when measured using automated platelet 
counters(86). 
Fay et al reported a significant decrease in platelet counts during normal 
pregnancy which he attributed to increased consumption of platelets(87). 
White Cell Counts 
The vitamin A and placebo group showed a non significant increase in white cell 
counts during pregnancy. In both groups there were significant decreases in 
white cell counts between delivery and 1 week and between 1 week and 3 
months (see figure 8). The 3 month values (vitamin A 5.62 and placebo 5.56 X 
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109/1) in both groups were significantly lower than the baseline values (vitamin A 
7.80 and placebo 7.92 X 109/1). The groups were comparable at 3 months with 
no significant difference in their mean values. 
Alger et al found increased white cell counts from enrollment to delivery in both 
HIV+ and HIV- mothers(42). Pitken et al reported decrease in the total white cell 
count in the 3rd trimester which continued after delivery. Their 6 week post 
partum values (non pregnant basal values) ranged between 4.32 - 7.64 X 
109/1(90). Both groups of our cohort at 3 months were within a similar range. 
Lymphocytes 
Lymphocyte counts showed significant increases between baseline and 3 
months in the vitamin A and placebo groups (see figure 9). At 3 months the 
groups were comparable with no significant difference in their mean values. In 
both groups there was no change during pregnancy, a significant increase by 1 
week and no change between 1 week and 3 months. 
Various authors (52,53, 90,91,92) have reported lower absolute lymphocyte 
numbers during pregnancy (not always significant) which increase after delivery. 
In this study the lymphocyte counts between 1 week and 3 months remained the 
same in the vitamin A group (mean 2.17 - 2.17 x 109/1) while there was a non­
significant fall in the placebo group (2.15 - 2.04 x 109/1). Vitamin A may have a 
protective effect in maintaining the lymphocyte numbers but further studies are 
required to assess this. 
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Alger et al reported lower absolute lymphocyte counts at enrollment in a cohort of 
HIV infected women, which increased at the time of delivery (1.714 ➔ 2.214 x 
109/1) compared to values of the HIV negative cohort (2.365 ➔ 2.294 x 109/1) 
(42). These patients did not have vitamin A supplements. This observation was 
not made in either of the study groups but the trends were similar to those 
reported in the literature. 
B Cell (CD19) Percentage 
The two groups showed a significant decrease between delivery-1 week in their 
8 cell percentage counts and a significant increase between 1 week and 3 
months (see figure 10). At 3 months both groups were comparable. 
Dodson et al reported normal T and 8 cell populations in pregnancy(55). The 
mean percentages of B cells varied between 10-20% . This cohort showed 
similar results in the vitamin A and placebo groups. 
B Cell Absolute Counts 
In both groups significant increases were noted between 1 week and 3 months 
(see figure 11 ). Although the actual lymphocyte counts increased between 
delivery and 1 week the absolute 8 cell counts remained unchanged during this 
period. This suggests that the initial lymphocyte increase was most likely due to 
T cell and Natural Killer cell recovery. 
Reports on absolute 8 cell counts in pregnancy are conflicting. 
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Tallon et al reported that the absolute number of B lymphocytes decreased 
significantly in the third trimester of pregnancy and post partum(52). 
Baines et al found that pregnancy has little or no effect on the proportions of B 
cells in maternal peripheral blood(57). 
Strelkauskas et al reported an increase in the absolute B cell counts in 
pregnancy(56). 
In this study the 3 months absolute B cell counts were significantly higher than 
baseline levels with no difference between the groups. These values probably 
reflect the "non-pregnant" levels. By inference the baseline values and the 
values at delivery and 1 week were lower than these "non-pregnant" values. 
Natural Kiler Cell (CD56) Percentage 
The placebo group showed a non significant increase between baseline, 
delivery, and 1 week and a non-significant decrease at 3 months post partum 
(see figure 12). There was a significant increase for this parameter between 
baseline and 1 week in the vitamin A group. The vitamin A group showed a 
decrease between 1 week and 3 months. The percentages of CD56 positive 
Natural Killer cells at 3 months were virtually identical in the 2 groups. 
Kuhnert et al reported a Natural Killer cell percentage of 15.1 ± 7 .1 % in women 1 
week post partum(93). 
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Natural Killer Cell Absolute Count 
In the vitamin A and placebo group there was no significant changes between 
baseline and delivery. In both groups there was a significant increase in the 
absolute count between delivery and 1 week (see figure 13). The placebo group 
did not show any decrease at all study intervals. However the vitamin A group 
showed a decline twice. At 1 week post delivery there is a significant rise in the 
vitamin A group and a gradual fall is noted to 3 months. Theoretically, if blood 
samples had been collected 1 week after the baseline supplementation a rise 
in the counts of Natural Killer cells in the vitamin A group could have been 
recorded prior to the fall noted at delivery. However to verify this theory further 
studies are required to validate the transient booster effect of vitamin A on 
Natural Killer cells. 
Kuhnert et al reported a Natural Killer absolute count of 0.266 x 109/L in 
women 1 week post partum(93). 
Very limited research has been performed using as the CD56 Natural Killer cell 
marker in this setting. 
Activation Marker (12) Percentage 
No significant changes were noted for this parameter throughout the study. The 
two groups were comparable at 3 months with no statistically significant 
difference in their means ( see figure 14 ). 
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Activation Marker (12) Absolute Count 
There was no significant change between baseline and delivery although there 
was a downward trend. The vitamin A and placebo groups showed a similar and 
significant increase between delivery and 1 week post partum (see figure 15). At 
3 months the groups were comparable and the means showed no significant 
difference. The counts did not alter much between 1 week and 3 months. The 
two groups had no differences at any of the intervals. The increase between 
delivery and 1 week coincides with the changes noted in the total absolute 
lymphocyte counts (probably the recovery of the T and Natural Killer cells). The 
increase in the activation marker at this point probably indicates an activation of 
T cells. Monocytes expressing the activation marker 12 were excluded by the 
gating of lymphocytes only. 
Moore et al reported that the activation marker (la) percentage and absolute 




This was a large controlled study of the effects of vitamin A and beta-carotene 
supplementation during pregnancy. The results of this study are relevant to our 
study. Preliminary reports from the NNIP-S (Nepal Nutritive Intervention Project 
Sarlahi-2) study were presented at the XVIII IVACG Meeting in Cairo (1998). 
Some of the findings reported at this congress follow. Malnutrition and 
micronutritional deficiencies (chronic vitamin A deficiency) were significant 
problems in mothers and infants. Vitamin A treatment reduced maternal mortality 
by 38 % and morbidity by 31 % while Beta-carotene treatment reduced these by 
50% and 47% respectively. The incidence of night blindness in Nepal was 11 %. 
Treatment with vitamin A or Beta-carotene reduced night blindness significantly­
by 40% and 65% respectively. Vitamin A reduced anaemia during and after 
pregnancy and in infants. There was a reduction in the incidence of malaria in 
the vitamin A group. There was no increase in birth defects; a slight protective 
effect with decrease in severe cranial and ocular abnormalities was noted with 
vitamin A treatment. 
Importance of this Study 
At the time of conceptualisation of the hypothesis vitamin A supplementation had 
been shown to result in decreased morbidity and mortality in infants in Nepal. 
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SUMMARY 
In this study biochemical vitamin A deficiency was noted in approximately 38% 
of the patients at baseline. Anemia at baseline was present in 65.4% of the 
patients. Haemoglobin levels showed a significant increase in both groups at 3 
months. The placebo group recovered earlier than the vitamin A group. Their 
haematocrits values were proportional to the haemoglobin values at baseline. 
The haematocrit values increased earlier in the vitamin A group (delivery to 1 
week) than the placebo group (1 week to 3 months). 
Six patients had thrombocytopenia at baseline. In both groups counts increased 
after delivery with a subsequent fall at 3 months. The platelet counts during 
pregnancy were lower than in the non - pregnant state (baseline compared to 3 
months). 
Of the patients studied 5.2% had white cell counts <5.0 X 109/1 at baseline. 
Both groups showed a significant decrease between delivery and 1 week and 1 
week and 3 months. Pregnancy is associated with increased white cell counts 
which corrects after delivery. 
Lymphopenia was noted in 9.1 % of the patients at baseline. Total absolute 
lymphocyte counts showed a significant increase between delivery and 1 week 
post delivery in both groups. There was no fall in the vitamin A group and a non 
significant fall in the placebo group. 
8 lymphocyte counts at baseline were similar to counts reported in normal 
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pregnancy. The white cell count decreased, and the total lymphocyte count 
increased early (1 week after delivery). B lymphocyte recovery occurred 
between 1 week and 3 months. T cells and Natural Killer cells are presumed to 
have recovered earlier. Values for B lymphocytes were lower during pregnancy. 
The Natural Killer cell counts were comparable in the two groups at baseline. 
Placebo group did not show decrease at any of the intervals, while the Natural 
Killer cells showed decreases at delivery (non significant) and at 3 months in the 
vitamin A group. 
Activation marker (12) showed an increase at baseline (32 - 33%) 
compared to 20% reported in the literature for normal pregnancy. There was an 
increase between delivery and 1 week probably reflecting the activation of T 
cells. 
This study found no significant effect of vitamin A on the B cells at any point. 
Although Natural Killer cells showed a non-significant increase in the vitamin A 
group the counts in the vitamin A group fell below the placebo group at delivery 
and at 3 months. If there was a "booster" effect it was very transient. However 
the point of concern is that the Natural Killer cells in the vitamin A group fell 
below the placebo group at 3 months. No differences were noted in the 
activation marker in the 2 groups at any point. No beneficial or detrimental effect 
was noted for vitamin A for the above parameters. 
In the Nepal study patients having night blindness were symptomatic with 
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vitamin A deficiency suggesting that the deficiency was more severe. Vitamin A 
deficiency is a chronic problem which is compounded by malnutrition, infection, 
including malaria and parasitism in Nepal. The big reduction in maternal 
mortality was not seen in our study probably because the cause of death was 
multifactorial in Nepal and due to the absence of maternal mortality 
in both our groups. 
CONCLUSION: 
• No beneficial effects were noted on natural killer cells, B lymphocytes and the
(12) activation marker.
Recommendations Arising from this Study: 
• To study normal non-HIV subjects in pregnancy to document various
haematological and immunological parameters with emphasis on the CD56
marker for natural killer cells. Very few reports are published and local data is
lacking
• To study the protective effect of vitamin A on the absolute lymphocyte




Differences in the Haematological Parameters between Baseline and Delivery in 
Vitamin A and Placebo groups 
VITAMIN A PLACEBO 
BASELINE DELIVERY BASELINE 
n 103 45 105 
Hb 10.51 10.83 10.63 
G/dl (10.26- 10. 76) (10.42 - 11.24) (10.41 -10.85) 
HCT 29.96 26.60 29.02 
% (26 89 - 31.03) (23.00 - 30.25) (27.51-30.54) 
PLT 258.40 264.47 253.30 
X109I1 (243.39 - 273.37) (236.38 - 292.57) (238.29-268.31) 
wee 7.80 8.63 7.92 
x109'1 (7.41 - 8.19 (7.37 - 9.90) (7.44-8.39) 
LYMPHS 1.77 1.72 1.71 
x109'1 (1.64 - 1.89) (1.50 - 2.00) (1.60 - 1.81) 














(1.60 - 2.00) 
Table 4 
Differences in the lmmunophenotype Markers between Baseline and Delivery in 
the Vitamin A and Placebo Groups 
VITAMIN A PLACEBO 
BASELINE DELIVERY BASELINE DELIVERY 
n 103 45 105 45 
CD56 10.42 10.80 10.15 10.51 
% (9.29 -11.55) (9.03- 12.57) (9.11 - 11.19) (9.24-11.79) 
CD56 
ABS 0.20 0.16 0.18 0.19 
X10911 (0.16 -0.24) (0.13 - 0.20) (0.16-0.21) (0.15- 0.23) 
CD19 10.26 9.99 10.87 10.87 
% (9.55 -10.97) (9.00 -10.98) (10.17-11.56) (9.82 - 11.92) 
·-
CD19 
ABS 0.18 0.20 0.19 0.19 
X109
11 (0.16- 0.20) (0.18 -0.22) (0.17 - 0.20) (0.16 -0.22) 
12 32.13 31.74 33.03 32.35 
% (27.93 -36.32) (26. 68 -36.81) (29.67 -36.39) (27. 79 -36.90) 
12 0.59 0.55 0.64 0.56 
ABS (0.50 -0.69) (0.41 -0.69) (0.45-0.83) (0.45- 0.67) 
X109/1 
Results are presented as a mean with (95% confidence intervals) 
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Table 5 
Differences in the Haematological Parameters between Baseline and 1 Week 
post partum in the Vitamin A and Placebo groups 
VITAMIN A PLACEBO 
BASELINE 1 WEEK BASELINE 
n 103 48 105 
Hb 10.51 11.81* 10.63 
G/dl (10.26-10.76) (11.37 -12.35) (10.41 -10.85) 
HCT 29.96 31.54 29.02 
% (26.89 -31.03) (28.47 -34.60) (27.51 -30.54) 
PLT 258.38 364.84* 253.30 
X 109/1 (243.39 - 273.37) (317.42 - 412.26) (238.29-268.31) 
wee 7.80 6.84* 7.92 
X 109/1 (7.41 -8.19) (6.23 - 7.44) (7.44 -8.39) 
LYMPHS 1.77 2.17* 1.71 
X 109/1 (1.64 -1.90) (2.00 -2.37) (1.60-1.81) 
















Differences in the lmmunophenotype Markers between Baseline and 1 Week 
post partum in the Vitamin A and Placebo groups 
VITAMIN A PLACEBO 
BASELINE 1 WEEK BASELINE 
n 103 48 105 
CD56 10.42 13.36* 10.15 
% (9.29 -11.55) (10.54-16.19) (9.11 -11 .11) 
CD56 
ABS 0.20 0.29* 0.18 
X 109/1 (0.16 -0.24) (0.23 -0.34) (0.16-0.21) 
CD19 10.26 8.42* 10.87 
% (9.55 -10.97) (7.58 - 9.25) (10.17 -11.56) 
CD19 
ABS 0.18 0.18 0.19 
X109/1 (0.16 -0.20) (0.16-0.21) (0.17 -0.20) 
12 32.13 34.56 33.03 
% (27.93 - 36.32) (30.09 -39.03) (29.67 -36.39) 
12 
ABS 0.59 0.73 0.64 
X 109/1 (0.50 -0.69) (0.62 -0.84) (0.45-0.83) 








(0.20 - 0.30) 
8.53* 






(0.56 - 0.86) 
Table 7 
Differences in the Haematological Parameters between Baseline and 3 Months 
post partum in the Vitamin A and Placebo groups 
VITAMIN A PLACEBO 
BASELINE 3 MONTH BASELINE 
n 103 46 105 
Hb 10.51 12.15* 10.63 
Gldl (10.26-10.76) (11.18-12.45) (10.41 - 10.85) 
HCT 28.96 33.58* 29.02 
% (26.89 -31.03) (30. 78 -36.38) (27.51 -30.54) 
PLT 258.38 282.16 253.39 
X 109/1 (243.39 - 273.37) (261.47 - 302.85) (238.29- 268.31) 
wee 7.80 5.62* 7.92 
X 109/1 (7.41 - 8.19) (5.15 -6.08) (7.44 -8.39) 
LYMPHS 1.77 2.17* 1.71 
X 109/1 (1.64 - 1.90) (1.93 - 2.42) (1.60 -1.81) 










(261.33 - 312.36) 
5.56* 
(5.07 - 6.06) 
2.04* 
(1.85 - 2.23) 
Table 8 
Differences in the lmmunophenotype Markers between Baseline and 3 Months 
post partum in the Vitamin A and Placebo groups 
VITAMIN A PLACEBO 
BASELINE 3 MONTH BASELINE 
n 103 46 105 
CD56 10.42 10.73 10.15 
% (9.29 -11.55) (9.09 - 12.38) (9.11 -11.19) 
CD56 
ABS 0.20 0.23 0.18 
X 109/1 (0.16- 0.24) (0.19 -0.26) (0.16 - 0.21) 
CD19 10.26 10.38 10.87 
(9.55 - 10.97) (9.09 - 11.67) (10.17 -11.56) 
CD19 
ABS 0.18 0.22* 0.19 
X 109/1 (0.16 - 0.20) (0.19 -0.24) (0.17 - 0.20) 
12 32.13 31.99 30.03 
% (27.93 -36.32) (26. 77 - 37.22) (29.67 -36.39) 
12 
ABS 0.59 0.68 0.64 
X 109/1 (0.50 -0.69) (0.57 - 0.79) (0.45-0.83) 


















Differences in the Haematological Parameters between Delivery and 1 Week 
post partum in the Vitamin A and Placebo groups 
VITAMIN A PLACEBO 
DELIVERY 1 WEEK DELIVERY 
n 45 48 45 
Hb 10.83 11.81 * 11.12 
G/dl (10.42 -11.25) (11.37 -12.25) (10.73- 11.51) 
HCT 26.60 31.54* 26.97 
% (22.96 -30.25) (28.47 -34.60) (23.30 - 30.64) 
PLT 264.47 364.84* 230.08 
X109/I (236.38 -292.57) (317.42 -412.26) (208.34 - 251 .81) 
wee 8.63 6.84* 8.38 
X109/I (7.37 - 9.90) (6.23 -7.45) (7.34 - 9.41) 
LYMPHS 1.72 2.17* 1.80 
X109/1 (1.50 - 2.00) (1.97 -2.37) (1.60- 2.00) 














(1.91 - 2.40) 
Table 10 
Differences in the lmmunophenotype Markers between Delivery and 1 Week post 
partum in the Vitamin A and Placebo groups 
VITAMIN A PLACEBO 
DELIVERY 1 WEEK DELIVERY 
n 45 48 45 
CD56 10.82 13.36 10.52 
% (9 03 • 12.57) (10.54-16.19) (9.24 - 11.80) 
CD56 0.16 0.29* 0.19 
ABS (0.13 - 0.20) (0.23 -0.34) (0.15- 0.23) 
X109/I 
CD19 9.99 8.42* 10.87 
% (9.00 - 10.98) (7.58 - 9.25) (9.82 - 11.92) 
CD19 0.29 0.18 0.19 
ABS (0.06- 0.51) (0.16-0.21) (0.16 - 0.22) 
X109/I 
12 31.74 34.06 32.35 
% (26. 68 - 36.81) (29.03 - 39.09) (27.79 - 36.90) 
12 
ABS 0.55 0.73* 0.56 
X109/I (0.41 - 0.6'9) (0.62 - 0.84) (0.45 - 0.67) 








(0.20 - 0.30) 
8.53* 
(7.35 - 9. 71) 
0.18 
(0.15 - 0.21) 
33.25 
(28.03 - 38.07) 
0.71* 
(0.56 - 0.86) 
Table 11 
Differences in the Haematological Parameters between Delivery and 3 Months 
post partum in the Vitamin A and Placebo groups 
VITAMIN A PLACEBO 
DELIVERY 3 MONTH DELIVERY 
n 45 46 45 
Hb 10.83 12.15* 11.12 
G/dl (10.42 - 11.25) (11.85 -12.45) (10.73-11.51) 
HCT 26.60 33.58* 26.97 
% (22.96 - 30.25) (30. 78 -36.38) (23.30 - 30.64) 
PLT 264.47 282.16 230.08 
X109/1 (236.38 - 292.57) (261.47 - 302.85) (208.34- 251.81) 
wee 8.63 5.62* 8.38 
X109/1 (7.37 -9.90) (5.15 -6.08) (7.34 - 9.41) 
LYMPHS 1.72 2.17* 1.80 
X109/I (1.50 - 2.00) (1.93-2.42) (1.60 - 2.00) 






(11.11 - 12.48) 
35.49* 
(34.30 - 36.68) 
286.84* 
(261.33 - 312.36) 
5.56* 
(5.07 - 6.06) 
2.04 
(1.85 - 2.23) 
Table 12 
Differences in the lmmunophenotype Markers between Delivery and 3 Months 
post partum in the Vitamin A and Placebo groups 
VITAMIN A PLACEBO 
DELIVERY 3 MONTH DELIVERY 
n 45 46 45 
CD56 10.80 10.73 10.51 
% (9.03 -12.57) (9.08 - 12.38) (9.24 - 11.80) 
CD56 
ABS 0.16 0.23* 0.19 
X10
9
/I (0.13 - 0.20) (0.19 - 0.26) (0.15-0.23) 
CD19 9.99 10.38 10.87 
% (9.00-10.98) (9.09 - 11.67) (9.82 -11.92) 
CD19 
ABS 0.19 0.22 0.19 
X10
9
/I (0.16 - 0. 21 ) (0.19 - 0.24) (0.16 -0.22) 
12 31.74 31.99 32.35 
% (26.68- 36.81) (26. 77 - 37.22) (27. 79 - 36.90) 
12 
ABS 0.55 0.68 0.56 
X109/1 (0.41 -0.69) (0.57 -0. 79) (0.45 -0.67) 














(30.49 - 39.87) 
0.71 
(0.59 - 0.83) 
Table 13 
Differences in the Haematological Parameters between 1 Week and 3 Months 
post partum in the Vitamin A and Placebo groups 
VITAMIN A PLACEBO 
1 WEEK 3 MONTH 1 WEEK 
n 48 46 45 
Hb 11.81 12.15 11.26 
G/dl (11.37 -12.25) (11.85 - 12.45) (10.80 -11. 72) 
HGT 31.54 33.58 30.20 
% (28.47 -34.60) (30. 78 - 36.38) (27.04 -33.36) 
PLT 364.84 282.16* 367.29 
X109/I (317.42 - 412.26) (261.47 - 302.85) (334.36 -400.21) 
wee 6.84 5.62* 7.86 
X109/I (6.23 - 7.45) (5.15 - 6.08) (6.18 -9.54) 
LYMPHS 2.17 2.17 2.15 
X109/I (2 00-2.37) (1.93-2.42) (1.91 - 2.40) 








(34.30 - 36.68) 
286.84* 
(261.33 - 312.36) 
5.56* 
(5.07 - 6.06) 
2.04 
(1.85 - 2.23) 
Table 14 
Differences in the lmmunophenotype Markers between 1 Week and 3 Months 
post partum in the Vitamin A and Placebo groups 
VITAMIN A PLACEBO 
1 WEEK 3 MONTH 1 WEEK 
n 48 46 45 
CD56 13.36 10.73 11.51 
% (10.54-16.19) (9.09 -12.38) (9.84-13.18) 
CD56 
ABS 0.29 0.23 0.25 
X109/I (0.23 - 0.34) (0.19 - 0.26) (0.20 -0.30) 
CD19 8.42 10.38* 8.53 
% (7.58 -9.25) (9.09 -11 .67) (7.35 -9. 71) 
CD19 
ABS 0.18 0.22 0.18 
X109/I (0.16-0.21) (0.19- 0.24) (0.15 - 0.21) 
12 34.56 31.99 33.25 
(30.09 -39.03) (26. 77 -37.22) (28.03- 38.47) 
12 
ABS 0.73 0.68 0.71 
X109/I (0.62 -0.84) (0.57 -0. 79) (0.56 - 0.86) 






(9.12 - 12.31) 
0.26 










MTI - mother-to-infant 
ANC - Ante natal clinic 
NK - Natural killer 
I U - international units 
RBP - Retinol binding protein 
CRBP - Cytoplasmic retinol binding protein 
RAR - Retinoic acid receptor 
RXR - Retinoic X receptor 
ADCC - Antibody dependent cell cytotoxicity 
SCIO - Severe combined immunodeficiency 
HLA - Human leucocyte antigen 
MHC - Major histocompatibility complex 
lg - lmmunoglobulin 
umol - micromols. 
ug - micrograms 
IF N - Interferon 
IL - Interleukin 
PCP - Pneumocystis carinii pneumonia 
SIV - Simian immunodeficiency virus 
HTL V - Human T-Lymphocyte virus 
RT - Reverse transcriptase 
RNA - Ribonucleic acid 
83 
Tat - Trans-activator 
Rev - Regulator of HIV structural proteins 
mRNA - messenger ribonucleic acid 
Nef - Negative factor 
Vif - Viral infectivity factor 
IP/ml - Infectious particles per milliliters. 
HSV - Herpes simplex virus 
CMV - Cytomegalovirus 
EBV - Epstein Barr virus 
TNF - Tumor necrosis factor 
GM-CSF - Granulocyte/monocyte colony stimulating factor 
CTL - Cytotoxic T-lymphocyte 
TGF - Transforming growth factor 
MTS - Mycobacterium tuberculosis 
MAC - Mycobacterium avium complex 
HPV - Human papillomavirus 
PIO - Pelvic inflammatory disease 
PTK - Protein tyrosine kinase 
BCRs - B cell receptors 
SCF - Stem cell factor 
lgM - lmmunoglobulin M 
lgD - lmmunoglobulin D 
PBL - Peripheral blood lymphocyte 
84 
gp - Glycoprotein 
PWM - Pokeweed mitogen 
SlgM - surface lmmunoglobulin M 
LGL - Large granular lymphocyte 
LAK - Lymphokine activated killer 
APA - Antiphospholipid antibody 
T cR - T eel I receptor 
LCMV - Lymphocytic choriomeningitis virus 
HSV-FS - Herpes simplex virus type I 
Ir - Immune response 
FITC - Fluorescein isothiocyanate 
FALS - Forward angle light scatter 
RALS - Right angle light scatter 
PE - Phycoerythrin 
PMT - Photomultiplier tube 
IFM - lmmunofluorescent microscopy 
PBMC - Peripheral blood mononuclear cells 
FS - Forward scatter 
LSS - Log side scatter 
LFL - Log fluorescence 
EDTA - Ethylenediamine tetra-acetic acid 
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